REGULATORY
MHLW Orders Label Revisions for Dexamethasone, Betamethasone to Warn of Phaeochromocytoma Crisis
The Ministry of Health, Labor and Welfare (MHLW) on May 13 ordered label revisions for drugs containing dexamethasone- or betamethasone-related steroids, calling for the addition of a warning regarding the risk of phaeochromocytoma crisis in patients taking these medicines. The…
To read the full story
Related Article
- PMDA Reviewing Safety Risks for Dexamethasone, Teicoplanin
March 28, 2022
REGULATORY
- Pharma Urges Pricing Rewards to Bolster Japan’s Drug Discovery Strength
September 24, 2026
- New Digital Minister Furukawa Pledges Push for Healthy Longevity
September 24, 2026
- MHLW Eyes Higher Long-Term Care Premiums for Wealthier Seniors
September 24, 2026
- Nippon Ishin’s Urano Named Senior Vice Health Minister in Takaichi Cabinet
September 24, 2026
- Ueno Vows to Advance Drug Innovation, Advanced Medicine in 2nd Term
September 24, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





